It is a second-generation EGFR TKI approved for the treatment of NSCLC for common (E19del and L858R) and uncommon (G719X, L861Q, and S768I) EGFR mutations and for patients with advanced squamous NSCLC after progression on previous therapy.15 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.